Celldex Therapeutics, Inc. SEC filings CLDX
Celldex Therapeutics, Inc. has 1,000 filings in SEC EDGAR's recent list, going back to Oct 31, 2007. Its latest annual report, Form ARS, was filed on Apr 29, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 6, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 22, 2026 (other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Jun 12, 2020 | — |
| CORRESP | Letter to the SEC | Jun 12, 2020 | — |
| UPLOAD | Letter from the SEC | Dec 12, 2019 | — |
| CT ORDER | Filing | Apr 20, 2018 | — |
| EFFECT | Filing | Feb 13, 2017 | — |
| EFFECT | Filing | Feb 13, 2017 | — |
| CORRESP | Letter to the SEC | Feb 9, 2017 | — |
| CORRESP | Letter to the SEC | Feb 9, 2017 | — |
| UPLOAD | Letter from the SEC | Feb 6, 2017 | — |
| CORRESP | Letter to the SEC | Jan 12, 2017 | — |
| UPLOAD | Letter from the SEC | Jan 5, 2017 | — |
| CORRESP | Letter to the SEC | Jan 4, 2017 | — |
| UPLOAD | Letter from the SEC | Dec 15, 2016 | — |
| D | Filing | Nov 29, 2016 | — |
| CT ORDER | Filing | Dec 17, 2014 | — |
| D | Filing | Oct 24, 2014 | — |
| UPLOAD | Letter from the SEC | Jan 3, 2014 | — |
| CORRESP | Letter to the SEC | Nov 27, 2013 | — |
| UPLOAD | Letter from the SEC | Nov 19, 2013 | — |
| EFFECT | Filing | Jan 16, 2013 | — |
| CORRESP | Letter to the SEC | Jan 9, 2013 | — |
| CORRESP | Letter to the SEC | Jan 4, 2013 | — |
| UPLOAD | Letter from the SEC | Jan 3, 2013 | — |
| UPLOAD | Letter from the SEC | Feb 22, 2011 | — |
| CORRESP | Letter to the SEC | Feb 9, 2011 | — |
| UPLOAD | Letter from the SEC | Feb 2, 2011 | — |
| CT ORDER | Filing | Feb 1, 2011 | — |
| CT ORDER | Filing | Feb 1, 2011 | — |
| CORRESP | Letter to the SEC | Jan 10, 2011 | — |
| UPLOAD | Letter from the SEC | Dec 23, 2010 | — |
| EFFECT | Filing | Apr 22, 2010 | — |
| EFFECT | Filing | Oct 30, 2009 | — |
| CORRESP | Letter to the SEC | Oct 29, 2009 | — |
| UPLOAD | Letter from the SEC | Oct 27, 2009 | — |
| EFFECT | Filing | Aug 28, 2009 | — |
| CORRESP | Letter to the SEC | Aug 27, 2009 | — |
| UPLOAD | Letter from the SEC | Aug 25, 2009 | — |
| UPLOAD | Letter from the SEC | Aug 13, 2009 | — |
| UPLOAD | Letter from the SEC | Jul 27, 2009 | — |
| 425 | Filing | Jun 9, 2009 | — |
| 425 | Filing | May 29, 2009 | — |
| CT ORDER | Filing | Mar 12, 2009 | — |
| UPLOAD | Letter from the SEC | Nov 18, 2008 | — |
| CORRESP | Letter to the SEC | Oct 6, 2008 | — |
| UPLOAD | Letter from the SEC | Sep 22, 2008 | — |
| CT ORDER | Filing | Sep 19, 2008 | — |
| CT ORDER | Filing | Jul 18, 2008 | — |
| NT 10-Q | Filing | May 9, 2008 | Mar 31, 2008 |
| NT 10-K | Filing | Mar 17, 2008 | Dec 31, 2007 |
| 8-A12G/A | Filing | Mar 7, 2008 | — |
| 425 | Filing | Feb 28, 2008 | — |
| EFFECT | Filing | Jan 22, 2008 | — |
| CORRESP | Letter to the SEC | Jan 22, 2008 | — |
| UPLOAD | Letter from the SEC | Jan 3, 2008 | — |
| 425 | Filing | Dec 14, 2007 | — |
| 425 | Filing | Nov 1, 2007 | — |
| 425 | Filing | Oct 31, 2007 | — |
Showing 57 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- In Vitro & In Vivo Diagnostic Substances (SIC 2835)
- Listed as
- CLDX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Hampton, NJ
- SEC filer status
- Large accelerated filer
- SEC CIK
- 744218
- Former names
- AVANT IMMUNOTHERAPEUTICS INC (until Sep 29, 2008); T CELL SCIENCES INC (until Aug 21, 1998)
Other In Vitro & In Vivo Diagnostic Substances companies
- Idexx Laboratories Inc /DE IDXX
- Lantheus Holdings, Inc. LNTH
- Neogen Corp NEOG
- Intellia Therapeutics, Inc. NTLA
- QuidelOrtho Corp QDEL
- Achieve Life Sciences, Inc. ACHV
- Myriad Genetics Inc MYGN
- Alpha Teknova, Inc. TKNO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.